Blood
Articles in this Issue
HLA-I aberrations in cutaneous T-cell lymphoma
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Abstract No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance with standard-of-care lenalidomide (R) alone after transplant. Herein, we report the...
Genetic alteration of class I HLA in cutaneous T-cell lymphoma
Abstract Abnormalities involving class I HLA are frequent in many lymphoma subtypes but have not yet been extensively studied in cutaneous T-cell lymphomas (CTCLs). We characterized...
Combined targeted modality in cHL: a risky bet?
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma
Abstract Treatment options for stage I/II bulky and advanced-stage disease have recently extensively changed. For decades in North America, ABVD (doxorubicin hydrochloride [Adriamyci...
IFN-I promotes T-cell–independent immunity and RBC autoantibodies via modulation of B-1 cell subsets in murine SCD
Abstract The pathophysiology of sickle cell disease (SCD) is characterized by hemolytic anemia and vaso-occlusion, although its impact on the adaptive immune responses remains incomp...
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection
Abstract Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant disorder. The current standard of care is not to screen for MGUS, so it is often in...
Daratumumab for maintenance in myeloma
Brentuximab vedotin and nivolumab for cHL
B-1 B cells lose self-control in SCD
How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma
Abstract Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable, malignancy, but older patients are at higher risk of relapsed disease because they may not be eligible f...
Is it time to screen for multiple myeloma?
Current myeloproliferative neoplasm scoring systems for clinical practice
Abstract BCR::ABL1-negative myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies that are caused by the proliferation of myeloid cells that harbor a JAK-STAT pathw...